Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328129 | 0.71 | KDM4E (0.41) | HTR2AHTR2CCYP3A4CYP2D6HTR6 | |
| SCHEMBL1327465 | 0.71 | TRPA1 (0.41) | HTR2AHTR2CCYP3A4CYP2D6HTR6 | |
| SCHEMBL1327443 | 0.66 | TRPA1 (0.44) | HTR2AHTR2CCYP3A4CYP2D6HTR6 | |
| SCHEMBL424172 | 0.65 | PKM (0.71) | PKMMEN1KMT2ATSHRATM | |
| SCHEMBL21442061 | 0.65 | ACHE (0.62) | CYP2D6PKMMEN1KMT2APKLR | |
| SCHEMBL21441975 | 0.65 | ACHE (0.62) | CYP2D6PKMMEN1KMT2APKLR | |
| SCHEMBL19013821 | 0.65 | AKR1C3 (0.51) | HTR2AHTR2CCYP3A4HTR6PKM | |
| SCHEMBL9965987 | 0.65 | HTR2A (0.58) | HTR2AHTR2C | |
| SCHEMBL21442038 | 0.63 | ACHE (0.43) | CYP2D6PKMMEN1KMT2ATSHR | |
| SCHEMBL5751186 | 0.62 | MMP2 (0.42) | HTR2AHTR2CCYP3A4CYP2D6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389383-B1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RES (IL) | 2019-04-24 | — | — | EP | disclosed |
| US-9034891-B2 | Bicyclic heterocyclic spiro compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2015-05-19 | — | — | US | disclosed |
| US-9034891-B2 | Bicyclic heterocyclic spiro compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2015-05-19 | — | — | US | disclosed |
| US-8673931-B2 | Bicyclic heterocyclic spiro compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2014-03-18 | — | — | US | disclosed |
| US-8673931-B2 | Bicyclic heterocyclic spiro compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2014-03-18 | — | — | US | disclosed |
| US-20130225624-A1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2013-08-29 | — | — | US | disclosed |
| US-20130225624-A1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2013-08-29 | — | — | US | disclosed |
| US-20110281903-A1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2011-11-17 | — | — | US | disclosed |
| US-20110281903-A1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2011-11-17 | — | — | US | disclosed |
| WO-2010084499-A9 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010084499-A2 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225624-A1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | CHRM3, CHRM1, CHRM2 | HTR2A 222/4885HTR2C 148/4885CYP3A4 533/4885 |
| US-20110281903-A1 | BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS | GPR119, CHRM2, CHRM1 | HTR2A 178/4885HTR2C 303/4885CYP3A4 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.